online-health-digital-technology-global-health-network-medical-tourism.jpg

We build technologies.
Not companies.

Healthcare IP · 30-Month Development · Exit-Ready

Acquire healthcare IP from universities, hospital groups, and physicians
Develop each technology through engineering, FDA compliance, and beta testing
License or sell to strategic buyers. Every technology is built to be acquired
AI-driven vetting identifies the best technologies and buyers before we invest a dollar
Each technology funded through its own SPV; capital efficient, focused, exit-ready

REQUEST INVESTOR ACCESS

No spam. Materials sent within one business day. Confidential.

THE MODEL

Acquire. Develop. Exit.

01

Built for exit from day one

02

Capital-efficient SPV structure

03

Regulation starts at acquisition

04

AI-accelerated at every stage

TECHNOLOGY PIPELINE

Our portfolio is bigger than you think.

We scored 130 technologies and narrowed to 20 active candidates. These are the most advanced. Each represents a defined market, a viable FDA pathway, and a known buyer landscape.

PHYSICIAN ADVISORY NETWORK

Clinical insight built into every program.

Practicing physicians and specialists across relevant clinical disciplines
Led by a designated Head of Doctors Network
Engaged at concept validation, development, and commercialization; not just at the end

Provides real-world clinical needs assessment and regulatory pathway input
Strengthens adoption among peers, payers, and health systems at exit
Members may also participate as qualified investors, bringing capital and credibility

Interested in working
with Promptus?

Whether you're an investor, a physician who wants to be part of the network, or a researcher with IP worth building, we want to hear from you.

Safe Harbor Statement & Important Disclosures. This page and any materials made available through it contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements involve known and unknown risks, uncertainties, and other factors that may cause actual results to differ materially from those expressed or implied. This page does not constitute an offer to sell or a solicitation of an offer to purchase any security. Any offering of securities will be made only by means of definitive offering documents and only to qualified investors. An investment in Promptus or any related special purpose vehicle involves a high degree of risk, including the possible loss of the entire amount invested. Past performance of any technology, portfolio company, or team member is not indicative of future results. Promptus is offering securities pursuant to an exemption from registration under Regulation D of the Securities Act of 1933, as amended. This offering has not been registered with the SEC or any state securities regulator. Prospective investors should conduct their own due diligence and consult with their own legal, tax, and financial advisors prior to making any investment decision. Pipeline technologies are in varying stages of development; some technologies may not reach commercialization. Market size estimates are based on publicly available third-party data and internal analysis and are subject to change.

We build technologies. Not companies.